Here's why the NIB (ASX:NHF) share price is on the rise today

The NIB Holdings Limited (ASX: NHF) share price is continuing to ascend today on the back of another positive update. Here's the details.

The NIB Holdings Limited (ASX: NHF) share price is continuing to ascend on the back of another positive update.

At the time of writing, the private health insurer's shares are swapping hands for $6.31, up 1%.

wooden blocks with percentage signs being built into towers of increasing height

Image source: Getty Images

What did NIB announce?

Investors appear pleased with the company's strategic direction, pushing NIB shares higher in early morning trade.

In a statement to the ASX, NIB advised it has sold its digital healthcare directory platform, Whitecoat to Commonwealth Bank of Australia (ASX: CBA).

Along with other shareholders, NIB approved the terms of the sale yesterday.

As a result, the company expects to receive roughly $9 million in profit before tax on the sale of its shareholding in Whitecoat.

In the 8 years of operation, Whitecoat has grown to become Australia's largest digital healthcare services directory. Currently, the online platform features more than 300,000 healthcare providers for consumers to find, book, and pay for treatment. In 2018, Whitecoat expanded its market presence by offering its services to New Zealand.

NIB managing director, Mark Fitzgibbon commented on the sale:

The sale to CBA will lift critical mass and the "network effect" these kinds of platforms rely upon. It will also bring the level of investment required to further develop Whitecoat's technology.

Just as Elon Musk doesn't manufacture every component of a Tesla nor will we see single companies build monolithic end to end solutions in the world of digital healthcare. Like for Tesla, our job at nib is to assemble the best tech functionality into a seamless and integrated experience for our members and providers. There remains so much more to do.

Mr Fitzgibbon highlighted that NIB never considered Whitecoat as part of its core strategy. This is because the online platform leans towards healthcare provider payments as opposed to health insurance plans. Furthermore, he assured that the sold-off business represents just one of many components of its total digital ecosystem for consumers and healthcare providers.

About the NIB share price

NIB shares have been on fire lately, storming close to 20% since releasing its trading update and outlook for FY21. It's worth noting, the company's shares reached a fresh 52-week high of $6.28 yesterday, before some slight profit-taking occurred.

NIB has a market capitalisation of roughly $2.8 billion, with approximately 457.7 million shares on issue.

Motley Fool contributor Aaron Teboneras owns shares of NIB Holdings Limited. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »